Search
Back

Tafamidis

CAS 594839-88-0
Tafamidis

General Information

Tafamidis free acid form is a non-nonsteroidal anti-inflammatory benzoxazole derivative. Tafamidis, sold under the brand name Vyndamax among others, was developed by FoldRX, now acquired by Pfizer. It was approved by FDA in 2019.


About the API

Therapeutic category Cardiovascular
Available formulations Oral Solid
Regulations
  • Japan DMF
  • Korea DMF
  • US DMF

Updates About Tafamidis

December 20, 2022
US DMF
February 15, 2024
US DMF

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.

For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.